Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study

Table 1 Baseline characteristics of the patients n (%)

Variables
Female	18 (54.4)
Mean age	13
Extent of disease
Proctitis	0
Left-side colitis	12 (30)
Extensive colitis	21 (70)
Current smokers	2 (11.1)
Endoscopic Mayo score 2-3	30 (100)
No previous endoscopy	3
Clinical situation before golimumab
Mild-remission	5 (15.2)
Moderate-severe	28 (84.8)
Golimumab indication
Induction of remission	28 (84.8)
Maintenance of remission	3 (9.1)
Extra-intestinal manifestations	2 (11.1)
Previous anti-TNF use	24 (72.7)
Use of > 1 anti-TNF	16 (48.5)
Previous anti-TNF failure
Primary non-responders	6 (25)
Loss of response	14 (58.3)
Infusion reaction	4 (16.6)
Previous steroid consumption (31 patients had previous steroid consumption)
Steroid-refractory	7 (27.3)
Steroid-dependent	24 (72.7)
Use of steroids at induction	25 (75.7)
Associated immunosuppressors	12 (36.6)
Azathioprine	11 (33.3)
Tacrolimus	1 (3)

Table 2 Bivariant analysis with steroid-free remission according to Mayo score at week 14 of golimumab treatment n (%)

Variable	NO SFR: n = 16 (48.5)	SFR: n = 17 (51.5)	P value
Age (yr)	38.36 ± 13.6	46.35 ± 13.7	NS
Mo since diagnosis	72.20 ± 96.11	74.65 ± 67.65	NS
Female sex	10 (62.5)	8 (47.1)	NS
Diagnosis < 2 yr	7 (46.7)	14 (82.4)	0.03
Anti-TNF naïve	3 (18.8)	6 (35.3)	NS
> 1 previous anti-TNF	9 (56.3)	7 (41.2)	NS
Steroid-dependent	15 (93.8)	9 (52.9)	0.01
Steroid-refractory	4 (25.0)	3 (17.6)	NS
mean ± SD

Table 3 Bivariant analysis with steroid-free clinical response according to Mayo score at week 14 of golimumab treatment, n (%)

Variable	No clinical response n = 8 (24.2)	Clinical response n = 25 (75.8)	P value
Age (yr)	42.71 ± 8.6	43.78 ± 14.9	NS
Mo since diagnosis	56.14 ± 68	77.35 ± 87.9	NS
Female sex	7 (87.5)	11 (44)	0.04
Diagnosis < 2 yr	4 (50)	17 (70.8)	NS
Anti-TNF naïve	3 (37.5)	6 (24)	NS
> 1 previous anti-TNF	4 (50.0)	12 (48.0)	NS
Steroid-dependent	8 (100)	16 (64.0)	0.05
Steroid-refractory	2 (25.0)	5 (20.0)	NS
mean ± SD